According to filings with the U.S. Securities and Exchange Commission, Immunis is raising up to $20,000,000.00 in new funding. Sources indicate that as part of senior management President, Hans Keirstead played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Immunis
Immunis Inc. is a private biotechnology company focused on the development of treatments for age-related and disease-related immune deficits. Immunis has developed a novel method to grow human cells for clinical use, and direct them to become highly pure populations of defined cells that secrete factors which benefit immune system development, modulation, and health. With age, every person experiences a reduction of factors which benefit immune system development, modulation, and health; our technology allows replacement of those factors. Our investigational product is all natural, all human, and represents a perfectly balanced set of immune modulators in naturally occurring relevant physiological concentrations. Immunis first clinical trial is a Phase 1/2a study of the effectiveness of STEM in treating muscle atrophy, which every person experiences with age.

To learn more about Immunis, visit http://www.immunisbiomedical.com/
Immunis Linkedin Page: https://www.linkedin.com/company/immunisbiomedical/

Contact:
Hans Keirstead, President
949-466-0380

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.